Welcome to CKB CORE's new home! Please be sure to update any bookmarks you may have.
×

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04127110
Title Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients (ALKALINE)
Acronym ALKALINE
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors European Organisation for Research and Treatment of Cancer - EORTC
Indications
Therapies
Age Groups: adult | senior
Covered Countries NLD | GBR | FRA | ESP | BEL

Additional content available in CKB BOOST